Clin2
NCT06515730Possibly a fitRecruiting

Apixaban vs warfarin for left ventricle clot after heart attack

Left Ventricular ThrombusAcute Myocardial Infarction

Treatments studied

Part of Heart & circulation clinical trials.

This trial tests whether a newer blood thinner, apixaban, works better than the standard warfarin for treating blood clots in the left ventricle after a heart attack. The goal is to see which medication is safer and more effective at preventing complications.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
212 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years old or older.
  • You have a blood clot in the left ventricle of your heart, confirmed by a heart ultrasound, within 1 to 28 days after your heart attack.
  • You are not currently taking a blood thinner for another reason (like a mechanical heart valve, atrial fibrillation, or blood clots elsewhere).
  • You do not have a high risk of bleeding (active bleeding, bleeding disorder, severe anemia, or low platelet count).
  • You do not have significant liver disease (like hepatitis or cirrhosis).
  • If you are a woman who could become pregnant, you must have a negative pregnancy test, not be breastfeeding, and use effective birth control.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07709780Recruiting· Phase 3
Comparing two blood thinners for left ventricle blood clots

This trial compares the blood thinner apixaban to warfarin for treating blood clots in the main pumping chamber of the heart (left ventricle). The goal is to see which medicine is better at preventing strokes and other complications.

Tucson, Arizona
NCT06742567Recruiting· Phase 3
Apixaban to prevent blood clots after a heart attack

This trial tests whether the blood thinner apixaban can prevent dangerous blood clots from forming in the heart's main pumping chamber after a specific type of heart attack. It is for patients who have severe weakness of the left ventricle and no clot already present.

Karachi, Sindh
NCT07246005Not yet recruiting· Phase 2
Shorter blood thinner treatment for left ventricular clot

This trial tests if patients with a blood clot in the left ventricle can safely stop blood thinner (Apixaban) after at least 3 months, instead of taking it longer. It may help people with no additional risks avoid extra medication.

London
NCT05794399Recruiting· Phase 4
Blood thinner after heart attack with clot seen on MRI

This trial tests how to use a blood thinner in people after a recent heart attack who have a clot in the left heart chamber confirmed by heart MRI. It may help lower the risk of the clot causing serious complications, but it also requires careful bleeding-safety screening.

Kathmandu, Bagmati
NCT07434661Not yet recruiting· Phase 3
Apixaban vs warfarin after heart valve surgery for atrial fibrillation

This study compares two blood thinners, apixaban (Eliquis) and warfarin, for people with atrial fibrillation who have just had heart valve surgery (repair or biological replacement). The goal is to see which medicine works better at preventing strokes and blood clots in the first three months after surgery.

Novosibirsk
NCT07471139Not yet recruiting· Phase 3
Apixaban vs warfarin for HeartMate 3 LVAD

This trial tests if the blood thinner apixaban (Eliquis) is as safe and effective as warfarin (Coumadin) for people with a HeartMate 3 LVAD heart pump. The goal is to find a simpler, more stable option for preventing blood clots.

Hear when a new Left Ventricular Thrombus trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.